Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.

@article{Thomas2015DiscoveryAD,
  title={Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.},
  author={Mark P Thomas and Barry V L Potter},
  journal={Journal of medicinal chemistry},
  year={2015},
  volume={58 19},
  pages={
          7634-58
        }
}
In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and women's health, including endometriosis. Drugs have been… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 188 REFERENCES

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL